Zobrazeno 1 - 10
of 16
pro vyhledávání: '"RC254-282"'
Autor:
In-Kyu Yoon, D. W. Vaughn, Karen W. Makar, Nicholas Jackson, Harry Kleanthous, Judith M. Silverman
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-10 (2021)
NPJ Vaccines
NPJ Vaccines
Vaccination of the global population against COVID-19 is a great scientific, logistical, and moral challenge. Despite the rapid development and authorization of several full-length Spike (S) protein vaccines, the global demand outweighs the current s
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-14 (2021)
NPJ Vaccines
NPJ Vaccines
Adenoviral vectors have been explored as vaccine agents for a range of infectious diseases, and their ability to induce a potent and balanced immune response made them logical candidates to apply to the COVID-19 pandemic. The unique molecular charact
Autor:
John P. A. Ioannidis
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-5 (2021)
NPJ Vaccines
NPJ Vaccines
Newly developed vaccines have tremendous potential in the fight against the COVID-19 pandemic. Risk compensation is the phenomenon where people receiving vaccines or other preventive measures may subsequently increase their previously suppressed expo
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-9 (2021)
NPJ Vaccines
NPJ Vaccines
The COVID-19 pandemic has prompted hundreds of laboratories around the world to employ traditional as well as novel technologies to develop vaccines against SARS-CoV-2. The hallmarks of a successful vaccine are safety and efficacy. Analytical evaluat
Autor:
Tompkins Kristin Rachael, Camila R. Fontes-Garfias, Kena A. Swanson, Pei Yong Shi, Mark Cutler, Jing Zou, Isis Kanevsky, Xuping Xie, Philip R. Dormitzer, David A. Cooper
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-4 (2021)
NPJ Vaccines
NPJ Vaccines
Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape fr
Autor:
Alejandra Barreto Grimaldos, Nikolaos C Kyriakidis, Eduardo Vásconez González, Andrés López-Cortés, Esteban Ortiz Prado
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-17 (2021)
NPJ Vaccines
NPJ Vaccines
The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and causes COVID-19 disease. The newly sequenced virus appears to originate in China and rapidly spread throughout the world, becoming a pandemic that, until January 5t
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
npj vaccines, 6(1):14
npj Vaccines
NPJ Vaccines
npj vaccines, 6(1):14
npj Vaccines
NPJ Vaccines
Bacillus Calmette–Guérin (BCG), the only vaccine proven to be effective against tuberculosis (TB), is the most commonly used vaccine globally. In addition to its effects on mycobacterial diseases, an increasing amount of epidemiological and experi
Autor:
Alessandra Vitelli, Roberto Camerini, Antonella Folgori, Simone Lanini, Silvia Meschi, Stefania Capone, Concetta Castilletti, Giulia Matusali, Stefano Colloca, Stefano Milleri, Eleonora Cimini, Chiara Agrati, Eleonora Tartaglia
Publikováno v:
NPJ Vaccines
npj Vaccines, Vol 6, Iss 1, Pp 1-4 (2021)
npj Vaccines, Vol 6, Iss 1, Pp 1-4 (2021)
Here we report on the humoral and cellular immune response in eight volunteers who autonomously chose to adhere to the Italian national COVID-19 vaccination campaign more than 3 months after receiving a single administration GRAd-COV2 vaccine candida
Autor:
Yue Gu, Youjia Zhong, Zubair Amin, Yuxi Niu, Melissa Shu Feng Ng, Yvonne Peng Mei Ng, Paul A. Tambyah, Jia Ming Low, Rashi Gupta, Paul A. MacAry, Liang Wei Wang, Le Ye Lee, Bhuvaneshwari D Shunmuganathan
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-8 (2021)
NPJ Vaccines
NPJ Vaccines
Lactating women can produce protective antibodies in their milk after vaccination, which has informed antenatal vaccination programs for diseases such as influenza and pertussis. However, whether SARS-CoV-2-specific antibodies are produced in human m
Autor:
Jennifer A. Barr, Kristen D. McAuley, Petrus Jansen van Vuren, Gough G. Au, Cameron R. Stewart, Sarah Edwards, Willy W. Suen, Brenton Rowe, Jean Payne, Hannah Bender, Christina L. Rootes, Nagendrakumar Balasubramanian Singanallur, Kathie Burkett, Matthew J. Neave, Teresa Lambe, Vittoria Stevens, Kim Halpin, Peter A. Durr, Glenn A. Marsh, Duane Walter, Clare Holmes, Suzanne Lowther, Elisha Soldani, Alexander J. McAuley, Seshadri S. Vasan, Daniel S. Layton, Matthew P. Bruce, Mary Tachedjian, Shawn Todd, Lee Trinidad, John Bingham, Sarah Jane Riddell, Rachel Layton, Sarah C. Gilbert, William S. J. Horman, Jenni Harper, Victoria Boyd, Kate Maynard, Naomi Watson, Teresa Eastwood, Trevor W. Drew, Tamara J Gough, Timothy Poole, Sheree Brown
Publikováno v:
NPJ Vaccines
npj Vaccines, Vol 6, Iss 1, Pp 1-8 (2021)
npj Vaccines, Vol 6, Iss 1, Pp 1-8 (2021)
Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectore